Publication | Open Access

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

Hematological MalignancyMedicineMalignant Blood DisorderImmunologyPharmacologyImmune Checkpoint InhibitorPharmacotherapyTargeted High-affinity InhibitorAnti-cancer AgentAntitumour ActivityImmunotherapyOncologyPhase 1Cancer Research